Exploring targeted therapies against RFPL3 for non-small cell lung cancer with lymph node metastasis.
[BACKGROUND] Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer-related deaths worldwide, marked by its aggressive nature and high likelihood of metastasis.
APA
Lin C, Jiang Y, Xu F (2025). Exploring targeted therapies against RFPL3 for non-small cell lung cancer with lymph node metastasis.. Discover oncology, 16(1), 2275. https://doi.org/10.1007/s12672-025-04116-4
MLA
Lin C, et al.. "Exploring targeted therapies against RFPL3 for non-small cell lung cancer with lymph node metastasis.." Discover oncology, vol. 16, no. 1, 2025, pp. 2275.
PMID
41276729
Abstract
[BACKGROUND] Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer-related deaths worldwide, marked by its aggressive nature and high likelihood of metastasis. The precise function of ret finger protein-like 3 (RFPL3) in NSCLC progression remains incompletely understood.
[METHODS] This study measured RFPL3 expression in NSCLC by immunohistochemistry, qPCR, and Western blot. RFPL3's effects on proliferation were assessed with CCK-8 and colony formation assays. Transwell and wound-healing assays evaluated its role in invasion, metastasis, and EMT. In vitro and in vivo studies determined RFPL3's mechanisms driving EMT and lymphatic metastasis.
[RESULTS] RFPL3 was overexpressed in NSCLC tissues, correlating with lymphatic metastasis and poor prognosis, establishing it as a distinct prognostic risk factor. Knockdown reduced NSCLC cell proliferation, invasion, and metastasis, while overexpression enhanced these malignant phenotypes. RFPL3 increased EMT-related protein expression by western blot, promoting tumor cell metastasis. In vivo, RFPL3 overexpression accelerated tumor growth and lymphatic metastasis in mice.
[CONCLUSION] This study revealed the critical role of RFPL3 in NSCLC, suggesting that RFPL3 might serve as both a biomarker and a therapeutic target for this type of cancer, which provides new insight for improving patient prognoses.
[METHODS] This study measured RFPL3 expression in NSCLC by immunohistochemistry, qPCR, and Western blot. RFPL3's effects on proliferation were assessed with CCK-8 and colony formation assays. Transwell and wound-healing assays evaluated its role in invasion, metastasis, and EMT. In vitro and in vivo studies determined RFPL3's mechanisms driving EMT and lymphatic metastasis.
[RESULTS] RFPL3 was overexpressed in NSCLC tissues, correlating with lymphatic metastasis and poor prognosis, establishing it as a distinct prognostic risk factor. Knockdown reduced NSCLC cell proliferation, invasion, and metastasis, while overexpression enhanced these malignant phenotypes. RFPL3 increased EMT-related protein expression by western blot, promoting tumor cell metastasis. In vivo, RFPL3 overexpression accelerated tumor growth and lymphatic metastasis in mice.
[CONCLUSION] This study revealed the critical role of RFPL3 in NSCLC, suggesting that RFPL3 might serve as both a biomarker and a therapeutic target for this type of cancer, which provides new insight for improving patient prognoses.
같은 제1저자의 인용 많은 논문 (5)
- Defining the heterogeneous molecular landscape of lung cancer cell responses to epigenetic inhibition.
- Cellular senescence: A novel mechanism of therapeutic resistance in prostate cancer.
- Genetic and Molecular Mechanisms Linking Breast Cancer to Meningioma Risk: Roles of EXO1, BRCA2, and ESR1.
- The vessels encapsulating tumor clusters (VETC) pattern is a negative predictor for first-line immune checkpoint inhibitors alone in unresectable hepatocellular carcinoma.
- Evaluating lactate metabolism for prognostic assessment and therapy response prediction in gastric cancer with emphasis on the oncogenic role of SLC5A12.